BR112014000876A2 - composições em gel de oximetazolina e métodos de uso - Google Patents

composições em gel de oximetazolina e métodos de uso

Info

Publication number
BR112014000876A2
BR112014000876A2 BR112014000876A BR112014000876A BR112014000876A2 BR 112014000876 A2 BR112014000876 A2 BR 112014000876A2 BR 112014000876 A BR112014000876 A BR 112014000876A BR 112014000876 A BR112014000876 A BR 112014000876A BR 112014000876 A2 BR112014000876 A2 BR 112014000876A2
Authority
BR
Brazil
Prior art keywords
rosacea
methods
telangiectasias
limitation
combinations
Prior art date
Application number
BR112014000876A
Other languages
English (en)
Inventor
Rodney Greenaway Evans Charles
Powala Christopher
Barry Brown Marc
Tiong Lim Sian
D Shanler Stuart
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112014000876A2 publication Critical patent/BR112014000876A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

abstract embodiments relating to gels comprising imidazoline alpha agonists, such as, without limitation, oxymetazoline or a pharmaceutically acceptable salt thereof, and methods for treating diseases, such as, without limitation, rosacea, including, for example, erythematotelangiectatic rosacea, papulopustular rosacea, phymatous rosacea, ocular rosacea or combinations thereof; and symptoms associated with rosacea, including, for example, papules, pustules, phymas (skin thickening), telangiectasias or erythema or redness associated with rosacea, other skin erythemas, telangiectasias, purpura or the like, and other manifestations associated therewith or combinations thereof using such gels are described herein. tradução do resumo resumo patente de invenção: "composições em gel de oximetazolina e métodos de uso". modalidades relacionadas a géis compreendendo agonistas de alfa imidazolina tais como, sem limitação, oximetazolina ou um sal farmaceuticamente aceitável da mesma e métodos para tratamento de doenças tais como, sem limitação, rosácea, incluindo, por exemplo, rosácea eritematotelangiectática, rosácea papulopustular, rosácea fimatosa, rosácea ocular ou combinações das mesmas; e sintomas associados com rosácea incluindo, por exemplo, pápulas, pústulas, fimas (espessamento da pele), telangiectasias ou eritema ou vermelhidão associado com rosácea, outros eritemas de pele, telangiectasias, púrpura ou similar, e outras manifestações associadas com os mesmos ou combinações dos mesmos usando tais géis são descritos aqui.
BR112014000876A 2011-07-14 2012-07-12 composições em gel de oximetazolina e métodos de uso BR112014000876A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161507926P 2011-07-14 2011-07-14
PCT/US2012/046547 WO2013010032A1 (en) 2011-07-14 2012-07-12 Gel compositions of oxymetazoline and methods of use

Publications (1)

Publication Number Publication Date
BR112014000876A2 true BR112014000876A2 (pt) 2017-02-21

Family

ID=46924508

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014000876A BR112014000876A2 (pt) 2011-07-14 2012-07-12 composições em gel de oximetazolina e métodos de uso

Country Status (10)

Country Link
US (1) US20130079379A1 (pt)
EP (1) EP2731606A1 (pt)
JP (1) JP2014523908A (pt)
KR (1) KR20140074883A (pt)
CN (1) CN103796652A (pt)
AU (1) AU2012281059A1 (pt)
BR (1) BR112014000876A2 (pt)
CA (1) CA2841632A1 (pt)
RU (1) RU2014104559A (pt)
WO (1) WO2013010032A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2648439C2 (ru) 2011-02-15 2018-03-26 Аллерган, Инк. Фармацевтическая композиция в виде крема, содержащая оксиметазолин, для лечения симптомов розацеа
BR112015027984A2 (pt) * 2013-05-06 2017-09-05 Allergan Inc Agonistas alfa adrenérgicos para o tratamento de lesão de tecido
CN105579042A (zh) * 2013-07-26 2016-05-11 格拉德曼研究与发展公司 治疗皮肤增厚的方法
JP6156501B2 (ja) * 2013-09-02 2017-07-05 株式会社島津製作所 クロマトグラムデータ処理装置
JP2017501224A (ja) * 2013-12-18 2017-01-12 ジー・エヌ・ティー・エル・エル・シー 緑内障の治療用組成物及び方法
MX2016016400A (es) * 2014-06-11 2017-06-12 Allergan Inc Formulaciones de oximetazolina estabilizadas y sus usos.
MX2017014471A (es) 2015-05-13 2018-06-11 Monopar Therapeutics Inc Clonidina y/o derivados de clonidina para uso en la prevención de la lesión de la piel resultante de la radioterapia.
WO2017132410A1 (en) 2016-01-26 2017-08-03 Frank Litvack Compositions and uses of alpha-adrenergic agents
FR3061434B1 (fr) * 2017-01-04 2019-07-12 Pierre Fabre Dermo-Cosmetique Composition cosmetique comprenant une association d'huile de pongamia et de pentylene glycol 4-t-butylcyclohexanol pour lutter contre la rosacee
CA3061196A1 (en) 2017-05-26 2018-11-29 Scott Whitcup A topical composition for treating rosacea and a method for treating rosacea with the same
CN110785161B (zh) 2017-06-23 2023-06-20 宝洁公司 用于改善皮肤外观的组合物和方法
US11376311B2 (en) * 2017-11-02 2022-07-05 Colorado Seminary, Owner and Operator of University of Denver Methods of treating microbial infection and inflammation
US11622963B2 (en) 2018-07-03 2023-04-11 The Procter & Gamble Company Method of treating a skin condition
EP3860592A4 (en) * 2018-11-26 2023-04-19 Cellix Bio Private Limited OPHTHALMIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN AND EYE DISEASES
US20220160697A1 (en) * 2019-03-19 2022-05-26 Nobelpharma Co., Ltd. Pharmaceutical composition having excellent drug absorption into the living body and excellent chemical stability
US11185532B2 (en) 2019-05-01 2021-11-30 Clexio Biosciences Ltd. Methods of treating pruritus
JP2023528616A (ja) 2020-06-01 2023-07-05 ザ プロクター アンド ギャンブル カンパニー ビタミンｂ３化合物の皮膚への浸透を改善する方法
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
US11179353B1 (en) * 2020-09-22 2021-11-23 Rythera Therapeutics, Inc. Composition and method for prevention and treatment of radiation dermatitis
US20220339082A1 (en) * 2021-04-23 2022-10-27 Colgate-Palmolive Company Solid Oral Care Compositions
CN113476397B (zh) * 2021-07-12 2022-11-18 海南海神同洲制药有限公司 一种甲硝唑凝胶及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19549421C2 (de) * 1995-11-10 1999-11-18 Klosterfrau Mcm Vetrieb Gmbh Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden
US5888493A (en) * 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
WO2004024225A1 (en) * 2002-09-16 2004-03-25 Zicam, Llc. System and method for delivering a composition to the nasal membrane
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
EP2329849B1 (en) * 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
BR112012024289A2 (pt) * 2010-03-26 2017-07-18 Galderma Res & Dev "método para fornecer um tratamento seguro e efetivo do eritema e composição de gel tópica"
CA2814975A1 (en) * 2010-10-21 2012-04-26 Galderma S.A. Topical gel composition

Also Published As

Publication number Publication date
CN103796652A (zh) 2014-05-14
RU2014104559A (ru) 2015-08-20
EP2731606A1 (en) 2014-05-21
KR20140074883A (ko) 2014-06-18
US20130079379A1 (en) 2013-03-28
WO2013010032A1 (en) 2013-01-17
CA2841632A1 (en) 2013-01-17
JP2014523908A (ja) 2014-09-18
AU2012281059A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
BR112014000876A2 (pt) composições em gel de oximetazolina e métodos de uso
BR112016030541A2 (pt) métodos para o tratamento de infecções fúngicas
BR112018004536A2 (pt) peptídeos de endereçamento à cartilagem
BR112015031903A2 (pt) composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto
EA201390682A1 (ru) Спирооксиндольные антагонисты mdm2
EA201390821A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты и их применение
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
BR112012021086A2 (pt) composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2017000498A1 (es) Una formulación de n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforida (galns)(divisional solicitud 219-2013)
BR112015014752A2 (pt) compostos e métodos para modulação de cinase, e indicações para isto
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
BR112012012529A2 (pt) composto indol e seu uso farmacêutico
BR112016015235A2 (pt) Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento
BR112012021905A2 (pt) tratamento de nefrite lúpica usando laquinimod
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
BR112015024234A2 (pt) composição de liberação sustentada injetável e método para o uso da mesma para tratar inflamação em articulações e dor associada com a mesma
BR112014012479A2 (pt) derivados de [1,2,3]triazol[4,5-d]pirimidina como agonistas das agonistas de receptor 2 de canabinóide
MX2013003638A (es) Tratamiento en combinacion para rosacea.
ITMI20120370A1 (it) Miscela antimicrobica e rivestimento per supportare la guarigione di ferite, che ha un effetto antimicrobico.
CN107406464A8 (zh) 精氨酸酶抑制剂及其治疗用途
BR112014006223A2 (pt) 6-substituídas-3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas como tirosina quinase c-met
BR112017012588A2 (pt) compostos heteroaril-heteroarila bicíclicos de ácido benzoico como agonistas de receptores beta do ácido retinoico (rarbeta)
EA201290808A1 (ru) Замещенные конденсированные производные имидазола, фармацевтические композиции и способы их применения
EA201591409A1 (ru) Бициклические соединения

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]